Abstract | PURPOSE: PATIENTS AND METHODS: Disease-free survival (DFS) and other outcomes were assessed in subgroups by ER and PgR status using Cox's proportional hazards model, adjusting for nodal status and prior adjuvant chemotherapy. RESULTS: The DFS hazard ratio (HR) for letrozole versus placebo in ER+/PgR+ tumors (N = 3,809) was 0.49 (95% CI, 0.36 to 0.67) versus 1.21 (95% CI, 0.63 to 2.34) in ER+/PgR- tumors (n = 636). ER+/PgR+ letrozole patients experienced significant benefit in distant DFS (DDFS; HR = 0.53; 95% CI, 0.35 to 0.80) and overall survival (OS; HR = 0.58; 95% CI, 0.37 to 0.90). A statistically significant difference in treatment effect between ER+/PgR+ and ER+/PgR-subgroups for DFS was observed (P = .02), but not for DDFS (P = .06) or OS (P = .09). CONCLUSION: These results suggest greater benefit for letrozole in DFS, DDFS, and OS in patients with ER+/PgR+ tumors, implying greater activity of letrozole in tumors with a functional ER. However, because this is a subset analysis and receptors were not measured centrally, we caution against using these results for clinical decision making.
|
Authors | Paul E Goss, James N Ingle, Silvana Martino, Nicholas J Robert, Hyman B Muss, Martine J Piccart, Monica Castiglione, Dongsheng Tu, Lois E Shepherd, Kathleen I Pritchard, Robert B Livingston, Nancy E Davidson, Larry Norton, Edith A Perez, Jeffrey S Abrams, David A Cameron, Michael J Palmer, Joseph L Pater, National Cancer Institute of Canada Clinical Trials Group MA.17 |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 25
Issue 15
Pg. 2006-11
(May 20 2007)
ISSN: 1527-7755 [Electronic] United States |
PMID | 17452676
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Nitriles
- Placebos
- Receptors, Estrogen
- Receptors, Progesterone
- Triazoles
- Tamoxifen
- Anastrozole
- Letrozole
|
Topics |
- Anastrozole
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy, metabolism, pathology)
- Canada
(epidemiology)
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Double-Blind Method
- Female
- Humans
- Letrozole
- Middle Aged
- Nitriles
(administration & dosage)
- Placebos
- Postmenopause
- Receptors, Estrogen
(metabolism)
- Receptors, Progesterone
(metabolism)
- Retrospective Studies
- Survival Rate
- Tamoxifen
(administration & dosage)
- Treatment Outcome
- Triazoles
(administration & dosage)
|